GlassScriptPhysician profile
Michelle M Nguyen
NPI 1225466311
$4,129.88
in general payments reported to CMS, 2019-2025
25 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.15 · 2022: $216 · 2023: $752 · 2024: $1,450 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $731.68 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $438.20 | 2023-2025 | |
| Lilly USA, LLC | $432.35 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $421.84 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $414.09 | 2022-2025 | |
| Amgen INC. | $341.90 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $322.30 | 2021-2025 | |
| Astellas Pharma US INC | $145.34 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $131.40 | 2024-2025 | Cologuard Collection Kit |
| Stemline Therapeutics INC. | $98.04 | 2022 | |
| Medline Industries LP | $96.39 | 2023-2024 | |
| Shield Therapeutics INC | $95.80 | 2023-2024 | Accrufer |
| Avion Pharmaceuticals | $69.01 | 2021-2022 | |
| Glaxosmithkline, LLC. | $67.95 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.45 | 2023-2025 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $46.87 | 2024-2025 | Auvelity |
| Abbott Laboratories | $42.62 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $35.39 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $32.47 | 2024 | |
| Idorsia Pharmaceuticals US INC | $27.85 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $24.20 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $17.98 | 2025 | Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $16.27 | 2025 | Nexletol |
| Exeltis, USA INC. | $15.89 | 2025 | Slynd |
| Mayne Pharma Commercial LLC | $14.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.